Market closed
Aura Biosciences/$AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
$AURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
108
Website
Aura Biosciences Metrics
BasicAdvanced
$250M
-
-$1.75
0.30
-
Price and volume
Market cap
$250M
Beta
0.3
52-week high
$11.39
52-week low
$4.84
Average daily volume
378K
Financial strength
Current ratio
10.771
Quick ratio
10.132
Long term debt to equity
10.278
Total debt to equity
12.35
Management effectiveness
Return on assets (TTM)
-27.46%
Return on equity (TTM)
-46.01%
Valuation
Price to book
1.64
Price to tangible book (TTM)
1.64
Price to free cash flow (TTM)
-3.044
Growth
Earnings per share change (TTM)
-9.22%
3-year earnings per share growth (CAGR)
-41.96%
What the Analysts think about Aura Biosciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Aura Biosciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Aura Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Aura Biosciences News
AllArticlesVideos
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewsWire·1 week ago
Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)
Seeking Alpha·2 weeks ago
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $250M as of April 12, 2025.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of April 12, 2025.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of April 12, 2025.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.